Wolf Group Capital Advisors Invests $261,000 in AstraZeneca PLC (NASDAQ:AZN)

Wolf Group Capital Advisors acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,555 shares of the company’s stock, valued at approximately $261,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AZN. Banque Transatlantique SA bought a new position in AstraZeneca during the 4th quarter valued at about $26,000. Confluence Investment Management LLC bought a new position in AstraZeneca during the 1st quarter valued at about $27,000. Mascagni Wealth Management Inc. bought a new position in AstraZeneca during the 4th quarter valued at about $29,000. FNY Investment Advisers LLC bought a new position in AstraZeneca during the 1st quarter valued at about $29,000. Finally, Highline Wealth Partners LLC lifted its holdings in AstraZeneca by 447.4% during the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company’s stock valued at $31,000 after purchasing an additional 340 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, BNP Paribas initiated coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 price target for the company. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $85.00.

AstraZeneca Trading Down 0.3%

Shares of NASDAQ AZN opened at $70.76 on Thursday. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The company has a market cap of $219.45 billion, a PE ratio of 28.42, a P/E/G ratio of 1.30 and a beta of 0.38. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average of $70.15 and a two-hundred day moving average of $70.36.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The company had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same period in the previous year, the firm posted $2.06 earnings per share. The company’s revenue was up 7.2% on a year-over-year basis. As a group, equities analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.